<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052400</url>
  </required_header>
  <id_info>
    <org_study_id>16-04-2482</org_study_id>
    <nct_id>NCT03052400</nct_id>
  </id_info>
  <brief_title>Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety
      of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated
      with Cushing's syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety
      of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated
      with Cushing's syndrome, and sub-optimally controlled on basal insulin, with or without
      prandial insulin and/or maximally-tolerated doses of metformin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>3 months</time_frame>
    <description>Glycemic lowering</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>3 months</time_frame>
    <description>BMI in kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage total body fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage total body lean mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>3 months</time_frame>
    <description>HOMA and OGTT dynamic measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipids</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting lipids and lipoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Systolic and diastolic BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>3 months</time_frame>
    <description>Symptomatic mild and severe hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Non-hypoglycemia-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>3 months</time_frame>
    <description>Total daily insulin dosage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Mifepristone 600 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone 600 mg daily</intervention_name>
    <description>Glucocorticoid receptor antagonist</description>
    <arm_group_label>Mifepristone 600 mg daily</arm_group_label>
    <other_name>Korlym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Males

          -  Age 18-65 inclusive

          -  Established T2DM for ≥ 1 year

          -  Taking stable doses (≤ 20% change in total daily insulin dose within 2 months prior to
             screening) of basal insulin, with or without prandial insulin (total daily dose must
             be ≤ 200 units)

          -  Baseline hemoglobin A1c (HbA1c) 8.0%-10.5%

          -  No use of any anti-hyperglycemic agents (oral or injectable) other than metformin or
             insulin

          -  No history or clinical suspicion of type 1 diabetes mellitus

          -  No concurrent chronic use of any corticosteroids by any route and for any indication,
             or concurrent conditions that may require the initiation of glucocorticoids during the
             study

          -  No concurrent lipid-lowering medications whose levels are dependent on CYP3A pathway
             clearance (e.g., simvastatin, lovastatin, atorvastatin, fluvastatin and rosuvastatin)
             should either be washed out for at least one month prior to enrollment and/or switched
             to alternative LDL-cholesterol lowering agents (e.g., pravastatin or ezetimibe) for at
             least one month.

          -  No contraindications or known intolerance to mifepristone

          -  No concurrent use of strong CYP3A inhibitors (e.g., cyclosporine, ergotamine,
             fentanyl, quinidine, sirolimus, tacrolimus, imidazole antifungals, HIV protease
             inhibitors, certain macrolide antibiotics)

          -  No concurrent use of CYP3A inducers (e.g., phenytoin, phenobarbital, carbamazepine,
             rifampin)

          -  No concurrent use of medications that may prolong the QT interval (e.g., selected
             antipsychotics and antidepressants, quinolone antibiotics)

          -  No daily use of warfarin or non-steroidal anti-inflammatory agents

          -  Baseline K+ and Mg+2 within the laboratory normal ranges, with or without oral K+
             and/or Mg+2 supplementation

          -  Fasting plasma glucose (FPG) averaging &lt; 280 mg/dL and without polyuria or polydipsia

          -  No symptomatic hypoglycemia averaging &gt; once per day

          -  Able and willing to perform self-monitoring of blood glucose (SMBG)

          -  Mean BP &lt; 140 mmHg systolic or 90 mm Hg diastolic

          -  Baseline LDL-cholesterol &lt; 200 mg/dL if on lipid-lowering therapy or &lt; 250 mg/dL while
             not on lipid-lowering therapy

          -  Fasting triglycerides ≤ 500 mg/dL if on lipid-lowering therapy

          -  HDL-cholesterol ≥ 25 mg/dL

          -  No known history of prostate cancer, or elevated level of prostate-specific antigen
             (PSA) at screening

          -  Estimated GFR ≥ 30 mL/min

          -  No concurrent endocrinopathies that have not been stabilized with replacement or other
             definitive therapies (including known adrenal insufficiency regardless of replacement
             therapy, cortisol &lt; 5 μg/dL at screening)

          -  No active hemolytic anemias or hemoglobin variants that render the measurement of
             HbA1c potentially unreliable

          -  No other clinically significant hepatic, cardiovascular (including known personal or
             family history of, or risk factors for long-QT syndrome, QTcF prolongation on ECG &gt;
             500 ms), infectious (including HIV or any viral hepatitis), inflammatory, neoplastic
             or other systemic disease that may contraindicate the change of lipid-lowering
             therapy, renders mifepristone unsafe, or otherwise confounds data interpretation

          -  Subjects not likely to start other drugs that may influence the study's outcomes
             (e.g., weight loss agents)

          -  Subjects who are able and willing to comply with all components of the study protocol,
             attend all scheduled follow-up visits, or who do not present other foreseeable
             barriers that might make the implementation of the protocol problematic or confound
             data interpretation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley H Hsia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Duran</last_name>
    <phone>323-357-3428</phone>
    <email>petraduran@cdrewu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanley H Hsia, MD</last_name>
    <phone>323-357-3633</phone>
    <email>stanleyhsia@cdrewu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charles Drew University of Medicine and Science</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley H Hsia, MD</last_name>
      <phone>323-357-3633</phone>
      <email>stanleyhsia@cdrewu.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley Hsia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>Stanley Hsia</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>mifepristone</keyword>
  <keyword>glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing as per NIH funding requirements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

